Secondary Pulmonary Alveolar Proteinosis Associated With Ruxolitinib After Bone-Marrow Transplantation: A Case With Transient Improvement Following Drug Discontinuation
{{output}}
Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor used to treat steroid-refractory graft-versus-host disease, wherein pulmonary alveolar proteinosis (PAP) is a rare complication. We report the case of a 47-year-old woman developing respiratory failure 8 months... ...
